Clarus Therapeutics Holdings, Inc. (CRXT) Financial Statements (2024 and earlier)
Company Profile
| Business Address |
555 SKOKIE BOULEVARD, SUITE 340 NORTHBROOK, IL 60062 |
| State of Incorp. | DE |
| Fiscal Year End | December 31 |
| Industry (SIC) | 2836 - Biological Products, Except Diagnostic Substances (benchmarking) |
| More info | Complete Financial Analysis Financial Benchmarking |
Balance Sheet (Statement of Financial Position) ($ in thousands)
| 6/30/2022 MRQ | 12/31/2021 | 12/31/2020 | |||
|---|---|---|---|---|---|
| ASSETS | |||||
| Current Assets | |||||
| Cash, cash equivalents, and short-term investments | 26,415 | 655 | |||
| Cash and cash equivalents | 26,415 | 655 | |||
| Receivables | 6,341 | ||||
| Inventory, net of allowances, customer advances and progress billings | 14,214 | ||||
| Inventory | 14,214 | ||||
| Prepaid expense | 4,673 | 168 | |||
| Total current assets: | 51,643 | 824 | |||
| Noncurrent Assets | |||||
| Property, plant and equipment | 65 | ||||
| Other undisclosed noncurrent assets | 58,650 | ||||
| Total noncurrent assets: | 65 | 58,650 | |||
| TOTAL ASSETS: | 51,708 | 59,474 | |||
| LIABILITIES AND EQUITY | |||||
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts payable and accrued liabilities | 22,206 | 421 | |||
| Taxes payable | 172 | ||||
| Accounts payable | 13,945 | 179 | |||
| Accrued liabilities | 8,261 | 70 | |||
| Debt | 42,269 | ||||
| Other undisclosed current liabilities | 1,585 | ||||
| Total current liabilities: | 66,060 | 421 | |||
| Noncurrent Liabilities | |||||
| Liabilities, other than long-term debt | 1,567 | 18,711 | |||
| Deferred revenue | 2,013 | ||||
| Derivative instruments and hedges, liabilities | 1,567 | 16,699 | |||
| Total noncurrent liabilities: | 1,567 | 18,711 | |||
| Total liabilities: | 67,627 | 19,132 | |||
| Temporary equity, carrying amount | 35,342 | ||||
| Equity | |||||
| Equity, attributable to parent, including: | (15,919) | 5,000 | |||
| Common stock | 2 | ||||
| Additional paid in capital | 305,734 | 9,718 | |||
| Accumulated deficit | (321,655) | (4,718) | |||
| Other undisclosed equity, attributable to parent | 0 | ||||
| Total equity: | (15,919) | 5,000 | |||
| TOTAL LIABILITIES AND EQUITY: | 51,708 | 59,474 | |||
Income Statement (P&L) ($ in thousands)
| 6/30/2022 TTM | 12/31/2021 | 12/31/2020 | ||
|---|---|---|---|---|
| Revenues | 13,957 | |||
| Cost of revenue (Cost of Goods and Services Sold) | (2,720) | |||
| Gross profit: | 11,237 | |||
| Operating expenses | (50,969) | |||
| Operating loss: | (39,732) | |||
| Nonoperating expense | (885) | |||
| Interest and debt expense | (15,895) | |||
| Loss from continuing operations before equity method investments, income taxes: | (56,512) | |||
| Other undisclosed income from continuing operations before income taxes | 15,895 | |||
| Loss from continuing operations: | (40,617) | |||
| Loss before gain (loss) on sale of properties: | ✕ | (40,617) | ✕ | |
| Net loss attributable to parent: | (40,617) | |||
| Other undisclosed net income available to common stockholders, basic | 412 | |||
| Net loss available to common stockholders, diluted: | (40,205) | |||
Comprehensive Income ($ in thousands)
| 6/30/2022 TTM | 12/31/2021 | 12/31/2020 | ||
|---|---|---|---|---|
| Net loss: | (40,617) | |||
| Comprehensive loss, net of tax, attributable to parent: | (40,617) | |||
Statements Sources
The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.